Biosimilar Switching in Rheumatology: Nocebo Effects, Persistence and Communication at Switch
DOI:
https://doi.org/10.5281/zenodo.22649257Keywords:
Biosimilar Switching in Rheumatology; Translational medicine, Evidence synthesis; Clinical implementation, Health services researchAbstract
Biosimilar Switching in Rheumatology is an area of active development in translational medicine, with evidence that has
accumulated unevenly across its component questions. We review the current evidence base for biosimilar switching in
rheumatology, spanning analytical, clinical, implementation, governance, and economic dimensions, focusing on where practice
has converged and where it continues to vary, and set out the practical considerations relevant to a service considering its
adoption. We conclude that selective, context-specific use is best supported by the evidence currently available, rather than
uniform adoption or avoidance.
References
Alvez D, Dumitrescu A, et al. "Biosimilar Switching in Rheumatology: a systematic review". J Transl Med 8(2011): 80-86. DOI: 10.17219/acem/208596
Brankovic K, Kowalczyk B, et al. "Biosimilar Switching in Rheumatology: a methodological appraisal". Clin Pharmacol Ther 10(2014): 91-98. DOI: 10.7759/cureus.104086
Castellani R, Ristic C, et al. "Biosimilar Switching in Rheumatology: a multicentre analysis". Nat Rev Drug Discov 12(2017): 102-110. DOI: 10.1038/s41746-023-00852-5
Dumitrescu A, Andric D, et al. "Biosimilar Switching in Rheumatology: a prospective cohort study". Trials 14(2020): 113-122. DOI: 10.1016/j.mayocpiqo.2022.09.004
Eriksdottir B, Brankovic E, et al. "Biosimilar Switching in Rheumatology: a randomised evaluation". Drug Discov Today 16(2023): 124-134. DOI: 10.1177/08404704241291226
Farkas I, Ionescu F, et al. "Biosimilar Switching in Rheumatology: a consensus statement". Clin Cancer Res 18(2011): 135-146. DOI: 10.1093/medlaw/fwad013
Grabowski P, Petrescu G, et al. "Biosimilar Switching in Rheumatology: a retrospective analysis". BMJ Open 20(2014): 146-158. DOI: 10.2196/89834
Hendriksen W, Wojcik H, et al. "Biosimilar Switching in Rheumatology: a validation study". J Clin Epidemiol 22(2017): 157-170. DOI: 10.1007/s10916-024-02104-9
Ionescu F, Foscarini I, et al. "Biosimilar Switching in Rheumatology: a scoping review". Contemp Clin Trials 24(2020): 168-182. DOI:
3389/fdgth.2026.1896184 10. Jankowiak G, Grabowski J, et al. "Biosimilar Switching in Rheumatology: a health-economic analysis". Ther Innov Regul Sci 26(2023): 179-185. DOI: 10.3390/diagnostics15162117
Kowalczyk N, Novotna K, et al. "Biosimilar Switching in Rheumatology: a systematic review". Br J Clin Pharmacol 28(2011): 190-197. DOI: 10.4103/jrpp.jrpp_20_65
Lindqvist U, Urbanek L, et al. "Biosimilar Switching in Rheumatology: a methodological appraisal". PLoS Med 30(2014): 201-209. DOI: 10.3389/fdgth.2026.1763884
Marchetti D, Doncheva M, et al. "Biosimilar Switching in Rheumatology: a multicentre analysis". Lancet 32(2017): 212-221. DOI: 10.2196/48297
Novotna E, Eriksdottir N, et al. "Biosimilar Switching in Rheumatology: a prospective cohort study". N Engl J Med 34(2020): 223-233. DOI: 10.1007/s00330-025-12031-z
Ostrowski L, Lindqvist O, et al. "Biosimilar Switching in Rheumatology: a randomised evaluation". JAMA 36(2023): 234-245. DOI: 10.3389/fdgth.2026.1699005
Petrescu S, Szabo P, et al. "Biosimilar Switching in Rheumatology: a consensus statement". Nat Med 38(2011): 245-257. DOI: 10.3389/fdgth.2026.1834800
Quintero B, Balogh Q, et al. "Biosimilar Switching in Rheumatology: a retrospective analysis". Cell Rep Med 40(2014): 256-269. DOI: 10.2196/69678
Ristic C, Castellani R, et al. "Biosimilar Switching in Rheumatology: a validation study". Clin Transl Sci 42(2017): 267-281. DOI: 10.7759/cureus.46454
Szabo J, Jankowiak S, et al. "Biosimilar Switching in Rheumatology: a scoping review". Pharmacogenomics J 44(2020): 278-284. DOI: 10.1016/j.ssci.2025.107028
Tarasov Q, Quintero T, et al. "Biosimilar Switching in Rheumatology: a health-economic analysis". Regul Toxicol Pharmacol 46(2023): 289-296. DOI: 10.2196/48633
Urbanek Z, Zielinski U, et al. "Biosimilar Switching in Rheumatology: a systematic review". Drug Saf 8(2011): 300-308. DOI: 10.1371/journal.pone.0305949
Vasquez A, Alvez V, et al. "Biosimilar Switching in Rheumatology: a methodological appraisal". Ann Intern Med 10(2014): 311-320. DOI: 10.1371/journal.pdig.0000514
Wojcik H, Hendriksen W, et al. "Biosimilar Switching in Rheumatology: a multicentre analysis". BMC Med 12(2017): 322-332. DOI: 10.17219/acem/208596
Zielinski O, Ostrowski Z, et al. "Biosimilar Switching in Rheumatology: a prospective cohort study". Sci Transl Med 14(2020): 333-344. DOI: 10.7759/cureus.104086
Andric V, Vasquez A, et al. "Biosimilar Switching in Rheumatology: a randomised evaluation". J Transl Med 16(2023): 344-356. DOI: 10.1038/s41746-023-00852-5
Balogh E, Emmerich B, et al. "Biosimilar Switching in Rheumatology: a consensus statement". Clin Pharmacol Ther 18(2011): 355-368. DOI: 10.1016/j.mayocpiqo.2022.09.004
Chiriac F, Farkas C, et al. "Biosimilar Switching in Rheumatology: a retrospective analysis". Nat Rev Drug Discov 20(2014): 366-380. DOI: 10.1177/08404704241291226
Doncheva M, Marchetti D, et al. "Biosimilar Switching in Rheumatology: a validation study". Trials 22(2017): 377-383. DOI: 10.1093/medlaw/fwad013
Emmerich T, Tarasov E, et al. "Biosimilar Switching in Rheumatology: a scoping review". Drug Discov Today 24(2020): 388-395. DOI: 10.2196/89834
Foscarini C, Chiriac F, et al. "Biosimilar Switching in Rheumatology: a health-economic analysis". Clin Cancer Res 26(2023): 399-407. DOI: 10.1007/s10916-024-02104-9
Alvez D, Dumitrescu A, et al. "Biosimilar Switching in Rheumatology: a systematic review". BMJ Open 28(2011): 410-419. DOI: 10.3389/fdgth.2026.1896184
Brankovic K, Kowalczyk B, et al. "Biosimilar Switching in Rheumatology: a methodological appraisal". J Clin Epidemiol 30(2014): 421-431. DOI: 10.3390/diagnostics15162117
Castellani R, Ristic C, et al. "Biosimilar Switching in Rheumatology: a multicentre analysis". Contemp Clin Trials 32(2017): 432-443. DOI: 10.4103/jrpp.jrpp_20_65
Dumitrescu A, Andric D, et al. "Biosimilar Switching in Rheumatology: a prospective cohort study". Ther Innov Regul Sci 34(2020): 443-455. DOI: 10.3389/fdgth.2026.1763884
Eriksdottir B, Brankovic E, et al. "Biosimilar Switching in Rheumatology: a randomised evaluation". Br J Clin Pharmacol 36(2023): 454-467. DOI: 10.2196/48297
Farkas I, Ionescu F, et al. "Biosimilar Switching in Rheumatology: a consensus statement". PLoS Med 38(2011): 465-479. DOI: 10.1007/s00330-025-12031-z
Grabowski P, Petrescu G, et al. "Biosimilar Switching in Rheumatology: a retrospective analysis". Lancet 40(2014): 476-482. DOI: 10.3389/fdgth.2026.1699005
Hendriksen W, Wojcik H, et al. "Biosimilar Switching in Rheumatology: a validation study". N Engl J Med 42(2017): 487-494. DOI: 10.3389/fdgth.2026.1834800
Ionescu F, Foscarini I, et al. "Biosimilar Switching in Rheumatology: a scoping review". JAMA 44(2020): 498-506. DOI: 10.2196/69678
Jankowiak G, Grabowski J, et al. "Biosimilar Switching in Rheumatology: a health-economic analysis". Nat Med 46(2023): 509-518. DOI: 10.7759/cureus.46454
Kowalczyk N, Novotna K, et al. "Biosimilar Switching in Rheumatology: a systematic review". Cell Rep Med 8(2011): 520-530. DOI: 10.1016/j.ssci.2025.107028
Lindqvist U, Urbanek L, et al. "Biosimilar Switching in Rheumatology: a methodological appraisal". Clin Transl Sci 10(2014): 531-542. DOI: 10.2196/48633
Marchetti D, Doncheva M, et al. "Biosimilar Switching in Rheumatology: a multicentre analysis". Pharmacogenomics J 12(2017): 542-554. DOI: 10.1371/journal.pone.0305949
Novotna E, Eriksdottir N, et al. "Biosimilar Switching in Rheumatology: a prospective cohort study". Regul Toxicol Pharmacol 14(2020): 553-566. DOI: 10.1371/journal.pdig.0000514
Ostrowski L, Lindqvist O, et al. "Biosimilar Switching in Rheumatology: a randomised evaluation". Drug Saf 16(2023): 564-578. DOI: 10.17219/acem/208596
Petrescu S, Szabo P, et al. "Biosimilar Switching in Rheumatology: a consensus statement". Ann Intern Med 18(2011): 575-581. DOI: 10.7759/cureus.104086
Quintero B, Balogh Q, et al. "Biosimilar Switching in Rheumatology: a retrospective analysis". BMC Med 20(2014): 586-593. DOI: 10.1038/s41746-023-00852-5
Ristic C, Castellani R, et al. "Biosimilar Switching in Rheumatology: a validation study". Sci Transl Med 22(2017): 597-605. DOI: 10.1016/j.mayocpiqo.2022.09.004
Szabo J, Jankowiak S, et al. "Biosimilar Switching in Rheumatology: a scoping review". J Transl Med 24(2020): 608-617. DOI: 10.1177/08404704241291226
Tarasov Q, Quintero T, et al. "Biosimilar Switching in Rheumatology: a health-economic analysis". Clin Pharmacol Ther 26(2023): 619-629. DOI: 10.1093/medlaw/fwad013
Urbanek Z, Zielinski U, et al. "Biosimilar Switching in Rheumatology: a systematic review". Nat Rev Drug Discov 28(2011): 630-641. DOI: 10.2196/89834
Vasquez A, Alvez V, et al. "Biosimilar Switching in Rheumatology: a methodological appraisal". Trials 30(2014): 641-653. DOI: 10.1007/s10916-024-02104-9
Wojcik H, Hendriksen W, et al. "Biosimilar Switching in Rheumatology: a multicentre analysis". Drug Discov Today 32(2017): 652-665. DOI: 10.3389/fdgth.2026.1896184
Zielinski O, Ostrowski Z, et al. "Biosimilar Switching in Rheumatology: a prospective cohort study". Clin Cancer Res 34(2020): 663-677. DOI: 10.3390/diagnostics15162117
Andric V, Vasquez A, et al. "Biosimilar Switching in Rheumatology: a randomised evaluation". BMJ Open 36(2023): 674-680. DOI: 10.4103/jrpp.jrpp_20_65
